SPDR S&P Biotech ETF
195 hedge funds and large institutions have $2.3B invested in SPDR S&P Biotech ETF in 2016 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 63 increasing their positions, 60 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
195
Holders Change
-4
Holders Change %
-2.01%
% of All Funds
5.2%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.13%
New
39
Increased
63
Reduced
60
Closed
40
Calls
$641M
Puts
$913M
Net Calls
-$271M
Net Calls Change
+$438M
Top Buyers
| 1 |
Goldman Sachs
New York
|
$591M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
$187M |
| 3 |
O
OrbiMed
New York
|
$50.7M |
| 4 |
Millennium Management
New York
|
$20.6M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
$17.2M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
$346M |
| 2 |
UBS Group
Zurich,
Switzerland
|
$96.7M |
| 3 |
JPMorgan Chase & Co
New York
|
$161M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
$121M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
$53.2M |
